Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?
Open Access
- 4 December 2018
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (2) , 236-244
Abstract
Therapeutic factor VIII is highly immunogenic. Despite intensive research in the last decades, the reasons why 5-30% of patients with hemophilia A (of all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement therapy remain an enigma. Under physiological conditions, endogenous factor VIII is recognized by the immune system. Likewise, numerous observations indicate that, in hemophilia A patients without inhibitors, exogenous therapeutic factor VIII is immunologically assessed and tolerated. A large part of the research on the immunogenicity of therapeutic factor VIII is attempting to identify the ‘danger signals’ that act as adjuvants to the deleterious anti-factor VIII immune responses. However, several of the inflammatory assaults concomitant to factor VIII administration initially hypothesized as potential sources of danger signals (e.g., bleeding, infection, and vaccination) have been disproved to be such signals. Conversely, recent evidence suggests that cells from inhibitor-negative patients are able to activate anti-inflammatory and tolerogenic mechanisms required to suppress deleterious immune responses, while cells from inhibitor-positive patients are not. Based on the available observations, we propose a model in which all hemophilia A patients develop anti-factor VIII immune responses during replacement therapy irrespective of associated danger signals. We further postulate that the onset of clinically relevant factor VIII inhibitors results from an inability to develop counteractive tolerogenic responses to exogenous factor VIII rather than from an exacerbated activation of the immune system at the time of factor VIII administration. A better understanding of the pathogenesis of neutralizing anti-factor VIII antibodies will have repercussions on the clinical management of patients and highlight new strategies to achieve active immune tolerance to therapeutic factor VIII.Keywords
This publication has 79 references indexed in Scilit:
- Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsBlood, 2013
- Induction of tolerance to factor VIII by transient co‐administration with rapamycinJournal of Thrombosis and Haemostasis, 2011
- HLA‐DR‐restricted T‐cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201PHaemophilia, 2010
- Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- A role for thrombin in the initiation of the immune response to therapeutic factor VIIIBlood, 2009
- Antioxidants reduce endoplasmic reticulum stress and improve protein secretionProceedings of the National Academy of Sciences, 2008
- The tick-over theory revisited: Formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb)Molecular Immunology, 2008
- A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytesProceedings of the National Academy of Sciences, 2007
- Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cellsThrombosis and Haemostasis, 2006
- Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.Journal of Clinical Investigation, 1994